intellectual properties

  • Therapy to reduce extravasation damage

    Patent number: 9504641 Abstract: A method of treating a patient who has extravasation of blood from an intravascular compartment to an extravascular compartment. An agent is administered to the patient which mitigates a harmful effect of break-down products of blood at an extravascular site, resulting in the patient having reduced morbidity and mortality. The morbidity and mortality of the patient is further reduced by concomitant administration of a suspension of submicron protein spheres having a molecular weight of ranging from 780 billion Daltons to less than 0.8 billion Daltons. Filed: September 6, 2012
    Inventor: Richard C. K. Yen
    Date of Patent: April 25, 2017

  • Nanoparticles for the treatment of radiation skin injury

    Patent number: 9629931 Abstract: The present invention is associated with a method of evaluating platelet function in vivo using skin-irradiation and nanoparticle radiation treatment. The present invention in the recovery of radiation skin injury suggests that radiation skin injury can be used as a substitute model to evaluate platelet substitute products instead of measuring bleeding times. Submicron nanoparticles and a future platelet treatment product are administered intravenously before and after irradiation to subjects. The resultant radiation skin injury are compared and used to evaluate the effectiveness of the platelet treatment product on platelet function in vivo. The radiation skin injury can serve as a model to evaluate platelet and platelet-substitute products, by replacing bleeding time measurements. Filed: March 26, 2014
    Inventor: Richard C. K. Yen
    Date of Patent: November 29, 2016

  • Submicron particles to decrease transfusion

    Patent number: 9351925 Abstract: A submicron protein sphere and method to intravenously treat a patient requiring blood component transfusion. The submicron protein spheres have a size ranging from 1.0 micron to less than 0.1 micron and a molecular weight ranging from 780 billion Daltons to less than 0.8 billion Daltons. The protein spheres have no biologically active molecules added or bound to the protein spheres prior to administering to the patient. The protein used to construct the spheres can be human serum albumin from natural sources or recombinant DNA-derived serum albumin, or other proteins such as gelatin or synthetic polypeptides. However, the protein spheres can bind the various clotting factors including fibrinogen after the spheres have entered the blood stream, binding the necessary additional biologically active molecules supplied in vivo from the patient's own blood, and possibly in vitro. Filed: September 6, 2012
    Inventor: Richard C. K. Yen
    Date of Patent: May 31, 2016

  • Submicron particles for the treatment of radiation damage in patients

    Patent number: 9226898 Abstract: A method of treating a patient exposed to radiation before the patient is thrombocytopenic, comprising: intravenous infusion of protein spheres at a concentration of the protein spheres sufficient to reduce the morbidity and mortality of the irradiated patient, wherein the protein spheres are formed from soluble proteins without the addition of surfactants or detergents, and the protein spheres spontaneously and directly bind at least one coagulation factor without the aid of other molecules which specifically bind the at least one coagulation factor. Filed: November 16, 2010
    Inventor: Richard C. K. Yen
    Date of Patent: January 5, 2016

  • Biologic devices for hemostasis

    Patent number: 9114127 Abstract: A microscopic protein device and the method of manufacture and the use of such a device for hemostasis. The device, made with biologic material such as serum albumin from a human or animal source, is less than five micron in any one dimension and typically less than one micron in diameter. It does not have any other biological or drug molecules attached to it in vitro. However, the device has properties that allow it to capture, concentrate, carry or bind biomodifying molecules, such as coagulation factor(s), or potentially other drugs, after exposure to plasma in vitro; and possibly in vivo as well. After infusion of said device intravenously inside the body, hemostatic effects can be demonstrated. Filed: April 22, 2008
    Inventor: Richard C. K. Yen
    Date of Patent: August 25, 2015

  • Fibrinogen-Coated Microspheres

    Issued to Dr. Richard Yen
    4/21/2001
    Australia Patent

  • Large Scale Production Process with Instantaneous Component Mixing & Controlled Sequential Mixing Characteristics

    Issued to Dr. Richard Yen
    6013285 - 1/11/2000

  • Method for Making Non-Crosslinked Protein Particles for Therapeutic & Diagnostic Use

    Issued to Dr. Richard Yen
    8/31/1999

  • Large Scale Production of Medicine Coated Crosslinked Protein Microspheres

    Issued to Dr. Richard Yen
    2/10/1998

  • Large Scale Production Process with Instantaneous Component Mixing & Controlled Sequential Mixing Characteristics Yen, Richard C.K. 08/986439 - 12/08/97
  • Protein Micromatrixes and method of Production

    Issued to Dr. Richard Yen
    1/22/1997

  • LARGE SCALE PRODUCTION OF MEDICINE COATED CROSSLINKEDPROTEIN MICROSPHERES Yen, Richard C.K. 08/487303 - 06/07/95
  • Protein Nanomatrixes and Method of Production

    US Patent No. 5,308,620.
    5/3/1994

    http://patentimages.storage.googleapis.com/pdfs/US5308620.pdf

  • Manufacturing Protein Microspheres

    US Patent No. 5,069,936.
    12/3/1991

    http://patentimages.storage.googleapis.com/pdfs/US5069936.pdf

  • Microsphere Coated Substrate Containing Reactive Aldehyde Groups

    US Patent NO. 4,438,239.
    Issued to Dr. Alan Rembaum and Dr. Richard Yen.
    3/20/1984

    http://patentimages.storage.googleapis.com/pdfs/US4438239.pdf

  • TitleInventorApplication No. - Filing DatePatent No. - Issue Date
    PROTEIN MICROMATRIXES AND METHOD OF PRODUCTIONYen, Richard C.K.91120485.7 - 11/29/91E 147976 - 01/22/97
    PROTEIN MICROMATRIXES AND METHOD OF PRODUCTIONYen, Richard C.K.91120485.7 - 11/29/91BE 0495187 - 01/22/97
    PROTEIN MICROMATRIXES AND METHOD OF PRODUCTIONYen, Richard C.K.91120485.7 - 11/29/91CH 0495187 - 01/22/97
    PROTEIN MICROMATRIXES AND METHOD OF PRODUCTIONYen, Richard C.K.91120485.7 - 11/29/91P69124357.3 - 01/22/97
    PROTEIN MICROMATRIXES AND METHOD OF PRODUCTIONYen, Richard C.K.91120485.7 - 11/29/91DK 0495187 - 01/22/97
    PROTEIN MICROMATRIXES AND METHOD OF PRODUCTIONYen, Richard C.K.91120485.7 - 11/29/910495187 - 01/22/97
    PROTEIN MICROMATRIXES AND METHOD OF PRODUCTIONYen, Richard C.K.91120485.7 - 11/29/91ES 0495187 - 01/22/97
    PROTEIN MICROMATRIXES AND METHOD OF PRODUCTIONYen, Richard C.K.91120485.7 - 11/29/91FR 0495187 - 01/22/97
    PROTEIN MICROMATRIXES AND METHOD OF PRODUCTIONYen, Richard C.K.91120485.7 - 11/29/91GB 0495187 - 01/22/97
    PROTEIN MICROMATRIXES AND METHOD OF PRODUCTIONYen, Richard C.K.91120485.7 - 11/29/91GR 0495187 - 01/22/97
    PROTEIN MICROMATRIXES AND METHOD OF PRODUCTIONYen, Richard C.K.91120485.7 - 11/29/9148820BE97 - 01/22/97
    PROTEIN MICROMATRIXES AND METHOD OF PRODUCTIONYen, Richard C.K.91120485.7 - 11/29/91LU 0495187 - 01/22/97
    PROTEIN MICROMATRIXES AND METHOD OF PRODUCTIONYen, Richard C.K.91120485.7 - 11/29/91NL 0495187 - 01/22/97
    PROTEIN MICROMATRIXES AND METHOD OF PRODUCTIONYen, Richard C.K.91120485.7 - 11/29/91SE 0495187 - 01/22/97
    NON-CROSSLINKED PROTEIN PARTICLES FOR THERAPEUTIC &DIAGNOSTIC USE Yen, Richard C.K. 08/212546 - 03/14/94 5616311 - 04/01/97
    NON-CROSSLINKED PROTEIN PARTICLES FOR THERAPEUTIC &DIAGNOSTIC USE Yen, Richard C.K. 08/471650 - 06/06/95 5725804 - 03/10/98
    Method for Making Non-Crosslinked Protein Particles for Therapeutic & Diagnostic Use Yen, Richard C.K. 08/747137 - 11/12/96 594503 - 08/31/99
    Fibrinogen-Coated MicrospheresYen, Richard C.K.78208/98 - 06/04/9804/21/01 Australia patent
    Fibrinogen-Coated MicrospheresYen, Richard C.K.09/090557 - 06/04/986264988 - 07/24/01
    Fibrinogen-Coated Particles for Therapeutic UseYen, Richard C.K.6391343 - 05/21/02